For decades, the pharmaceutical industry has invested heavily in scientific innovation, regulatory rigor, clinical development, manufacturing quality, and commercial excellence. Yet one of the most important links between innovation and patient impact has remained...
Merck’s $6.7bn Terns Deal: A New Oral CML Treatment
Merck has completed its $6.7 billion acquisition of Terns Pharmaceuticals, gaining control of TERN-701, an investigational oral CML treatment that the pharmaceutical giant hopes will become a cornerstone of its expanding cancer portfolio. The deal, which closed on 5...
Medicare GLP-1 Bridge: Weight-Loss Drug Coverage Begins 1st July
Starting, 1 July, millions of Medicare enrollees will gain coverage for weight-loss drugs for the first time, through a temporary pilot programme called the Medicare GLP-1 Bridge. The scheme covers Zepbound, Foundayo and Wegovy at a $50 monthly copayment and marks the...
The ‘Wild West’ of Peptide Medicine and Who’s Qualified to Prescribe
In the medical field, being “authorized” and “qualified” are two very different things. Authorized generally indicates you have the legal right to practice. Qualified means you have the expertise, experience, and skill needed to practice effectively. The distinction...
Beyond the Injection: The Future of Holistic GLP-1 Care
The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....
CagriSema: Strong Obesity Data, but can it Beat Tirzepatide?
CagriSema, the once-weekly obesity therapy from Novo Nordisk, has spent more than a year as the most closely watched candidate in metabolic medicine. The combination of cagrilintide and semaglutide promised weight loss beyond what either molecule could achieve alone....
Sustainable and Green Manufacturing Practices in the Life Sciences Industry
The life sciences sector is undergoing a significant transformation as it embraces sustainable and green manufacturing practices. These initiatives aim to reduce environmental impact, enhance operational efficiency, and meet the growing demand for eco-friendly...
Genentech Cuts 87 Jobs in Latest Round of Layoffs at South San Francisco HQ
Genentech has carried out another round of workforce reductions, cutting 87 positions at its South San Francisco headquarters. The layoffs, filed last week and set to take effect on September 15, were disclosed in a California Worker Adjustment and Retraining...
Navigating Life with Haemophilia with Pfizer
Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...
Merck Abandons £1bn UK Expansion, Citing Insufficient Government Support
US pharmaceutical heavyweight Merck has decided to halt its planned £1 billion expansion in the UK, criticising the government for a lack of substantial investment in the life sciences sector. The company, which operates under the name MSD in Europe, announced it will...
FDA Picks George Tidmarsh as Head of Drug Regulation Division
The Food and Drug Administration commissioner, Marty Makary, has selected George Tidmarsh, a former biotech executive and Stanford-affiliated pediatrician, to lead the agency’s drug regulatory arm, according to a source familiar with the matter. The appointment of...







